Tags

Type your tag names separated by a space and hit enter

Preventive and therapeutic HPV vaccines.
Curr Opin Investig Drugs 2007; 8(12):1038-50CO

Abstract

Cervical cancer is the second leading cause of cancer deaths in women worldwide and HPV infection is responsible for the development of this cancer. Effective vaccination against HPV represents an opportunity for the control of cervical cancer. The newly licensed preventive HPV vaccine in the US, Gardasil, has both a good safety profile and clinical efficacy against the HPV genotypes from which it was derived. However, this vaccine can only protect against up to 70 to 80% of cervical cancer and also lacks therapeutic efficacy against established HPV infection and HPV-associated lesions. Thus, the future of HPV vaccination needs to focus on the development of a new generation of preventive and therapeutic vaccines that are capable of protecting against most cervical cancers.

Authors+Show Affiliations

The Johns Hopkins Medical Institutions, Department of Pathology, 1550 Orleans Street, Baltimore, MD 21231, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

18058574

Citation

Monie, Archana, et al. "Preventive and Therapeutic HPV Vaccines." Current Opinion in Investigational Drugs (London, England : 2000), vol. 8, no. 12, 2007, pp. 1038-50.
Monie A, Hung CF, Wu TC. Preventive and therapeutic HPV vaccines. Curr Opin Investig Drugs. 2007;8(12):1038-50.
Monie, A., Hung, C. F., & Wu, T. C. (2007). Preventive and therapeutic HPV vaccines. Current Opinion in Investigational Drugs (London, England : 2000), 8(12), pp. 1038-50.
Monie A, Hung CF, Wu TC. Preventive and Therapeutic HPV Vaccines. Curr Opin Investig Drugs. 2007;8(12):1038-50. PubMed PMID: 18058574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preventive and therapeutic HPV vaccines. AU - Monie,Archana, AU - Hung,Chien-Fu, AU - Wu,T-C, PY - 2007/12/7/pubmed PY - 2008/3/26/medline PY - 2007/12/7/entrez SP - 1038 EP - 50 JF - Current opinion in investigational drugs (London, England : 2000) JO - Curr Opin Investig Drugs VL - 8 IS - 12 N2 - Cervical cancer is the second leading cause of cancer deaths in women worldwide and HPV infection is responsible for the development of this cancer. Effective vaccination against HPV represents an opportunity for the control of cervical cancer. The newly licensed preventive HPV vaccine in the US, Gardasil, has both a good safety profile and clinical efficacy against the HPV genotypes from which it was derived. However, this vaccine can only protect against up to 70 to 80% of cervical cancer and also lacks therapeutic efficacy against established HPV infection and HPV-associated lesions. Thus, the future of HPV vaccination needs to focus on the development of a new generation of preventive and therapeutic vaccines that are capable of protecting against most cervical cancers. SN - 1472-4472 UR - https://www.unboundmedicine.com/medline/citation/18058574/Preventive_and_therapeutic_HPV_vaccines_ L2 - https://www.who.int/reproductivehealth/publications/cancers/a92126/en/ DB - PRIME DP - Unbound Medicine ER -